Cover Image
Market Research Report
Product code 
942921

France Breast Cancer Diagnostics And Therapeutics Market 2019-2025

Published: | Orion Market Research Pvt Ltd | Delivery time: 2-3 business days

Price

Back to Top
France Breast Cancer Diagnostics And Therapeutics Market 2019-2025
Published: February 21, 2020
Orion Market Research Pvt Ltd
Delivery time: 2-3 business days
  • ALL
  • Description
  • Table of Contents
Description

France Breast Cancer Diagnostics And Therapeutics Market Size, Share & Trends Analysis Report by Cancer Type (DCIS, IDC, TNBC), Inflammatory Breast Cancer and Others), By Diagnostics (Mammography, Biopsy, PET/CET, Ultrasound, and Others), By Therapeutics(Laboratory testing and Point of care testing) and Forecast 2019-2025

France breast cancer diagnostics and therapeutics market are estimated to grow significantly at a CAGR of 9.1% during the forecast period. Increasing the incidence of breast cancer coupled with a growing awareness program towrds breast cancer diagnosis and treatment are the major factors that contributing to the growth of the market. According to the WHO, about 56,162 new breast cancer cases and 13,353 mortalities estimated in 2018. Institute curie is a key centre for the treatment of breast cancer in the country. The institute participating in more than 20 clinical trials for breast cancer on a variety of topics. The breast cancer screening program in France offers screening to women between 50 and 74 years of age which is covered by public health insurance.

France breast cancer diagnosis and therapeutics market are segmented on the basis of cancer type, diagnostics, and therapeutics. In cancer type segment market is further classified into ductal carcinoma in-situ (DCIS), invasive ductal carcinoma (IDC), triple negative breast cancer (TNBC), inflammatory breast cancer and others. In diagnostics technology, the segment market is further classified into mammography, biopsy, position emission tomography/computed tomography, ultrasound, and others. The therapeutics technology segment market is further segregated into chemotherapy, hormone therapy, targeted therapy, and others.

The companies which are contributing to the growth of France breast cancer diagnostics and therapeutics market include, Agendia NV, AstraZeneca PLC, Bayer AG, GlaxoSmithKline PLC, Mylan NV, Merck & Co., Inc., Novartis International AG, F. Hoffmann-La Roche AG, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.

Research Methodology

The market study of the France breast cancer diagnostics and therapeutics market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for biotechnology companies, research institutes, hospitals, and government organizations for the overall market and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. France breast cancer diagnostics and therapeutics Market Research and Analysis by Cancer Type

2. France breast cancer diagnostics and therapeutics Market Research and Analysis by Diagnostics

3. France breast cancer diagnostics and therapeutics Market Research and Analysis by Therapeutics

The Report Covers:

  • Comprehensive research methodology of the France breast cancer diagnostics and therapeutics market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the France breast cancer diagnostics and therapeutics market.
  • Insights about market determinants which are stimulating the France breast cancer diagnostics and therapeutics market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Table of Contents
Product Code: OMR2020959

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. France Breast Cancer Diagnostics and Therapeutics Market by Cancer Type
    • 5.1.1. Ductal Carcinoma In-Situ (DCIS)
    • 5.1.2. Invasive Ductal Carcinoma (IDC)
    • 5.1.3. Triple Negative Breast Cancer (TNBC)
    • 5.1.4. Inflammatory Breast Cancer
    • 5.1.5. Others (Invasive lobular carcinoma)
  • 5.2. France Breast Cancer Diagnostics and Therapeutics Market by Diagnostics
    • 5.2.1. Mammography
    • 5.2.2. Biopsy
    • 5.2.3. PET/CET
    • 5.2.4. Ultrasound
    • 5.2.5. Others (MRI)
  • 5.3. France Breast Cancer Diagnostics and Therapeutics Market by Therapeutics
    • 5.3.1. Chemotherapy
    • 5.3.2. Hormone Therapy
    • 5.3.3. Targeted Therapy
    • 5.3.4. Others (Radiation Therapy, Surgery)

6. Company Profiles

  • 6.1. Agendia NV
  • 6.2. AstraZeneca PLC
  • 6.3. Bayer AG
  • 6.4. GlaxoSmithKline PLC
  • 6.5. Mylan NV
  • 6.6. Merck & Co., Inc.
  • 6.7. Novartis International AG
  • 6.8. F. Hoffmann-La Roche AG
  • 6.9. Sanofi S.A.
  • 6.10. Siemens Healthcare GmbH

List of Tables

  • 1. FRANCE BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2018-2025 ($ MILLION)
  • 2. FRANCE BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS, 2018-2025 ($ MILLION)
  • 3. FRANCE BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2018-2025 ($ MILLION)

List of Figures

  • 1. FRANCE BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET SHARE BY CANCER TYPE, 2018 VS 2025 (%)
  • 2. FRANCE BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET SHARE BY DIAGNOSTICS, 2018 VS 2025 (%)
  • 3. FRANCE BREAST CANCER DIAGNOSTICS AND THERAPEUTICS MARKET SHARE BY THERAPEUTICS, 2018 VS 2025 (%)